60
Participants
Start Date
March 24, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
March 31, 2028
Targeted CEA CAR-T
Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest
Targeted CEA CAR-T
Subjects meeting the reinfusion criteria will receive pre-treatment with fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, rest for 1-2 days, and intraperitoneal reinfusion targeted CEA CAR-T therapy
RECRUITING
Changzheng Hospital, Naval Military Medical University, Shanghai, China, Shanghai
Chongqing Precision Biotech Co., Ltd
INDUSTRY